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Abstract: Growth hormone (GH)-secreting pituitary tumours represent the most genetically de-
termined pituitary tumour type. This is true both for germline and somatic mutations. Germline
mutations occur in several known genes (AIP, PRKAR1A, GPR101, GNAS, MEN1, CDKN1B, SDHx,
MAX) as well as familial cases with currently unknown genes, while somatic mutations in GNAS
are present in up to 40% of tumours. If the disease starts before the fusion of the epiphysis, then
accelerated growth and increased final height, or gigantism, can develop, where a genetic background
can be identified in half of the cases. Hereditary GH-secreting pituitary adenoma (PA) can manifest
as isolated tumours, familial isolated pituitary adenoma (FIPA) including cases with AIP mutations
or GPR101 duplications (X-linked acrogigantism, XLAG) or can be a part of systemic diseases like
multiple endocrine neoplasia type 1 or type 4, McCune–Albright syndrome, Carney complex or
phaeochromocytoma/paraganglioma-pituitary adenoma association. Family history and a search
for associated syndromic manifestations can help to draw attention to genetic causes; many of these
are now tested as part of gene panels. Identifying genetic mutations allows appropriate screening of
associated comorbidities as well as finding affected family members before the clinical manifestation
of the disease. This review focuses on germline and somatic mutations predisposing to acromegaly
and gigantism.
Keywords: acromegaly; AIP; gigantism; FIPA; MEN1; somatotroph adenoma; pituitary neuroen-
docrine tumour; X-linked acrogigantism
1. Introduction
Acromegaly is a rare, chronic disorder caused by excessive growth hormone (GH)
production. Common clinical manifestations include changes in appearance, headache,
joint pains as well as serious systemic complications such as metabolic, cardiovascular and
osteoarticular comorbidities especially axial arthritis and higher risk of tumour growth
(e.g., colon polyps and thyroid nodules) [1]. Cardiovascular diseases and cancer are mostly
responsible for an increased mortality in untreated patients [2,3]. Due to complications,
quality of life is significantly reduced [4]. In childhood and adolescence, an excessive
GH secretion before complete epiphyseal closure leads to gigantism, characterised by
abnormally tall stature. The prevalence of acromegaly is estimated between 28 to 137 per
million people [5]. In most studies, females are slightly more (1:1.24) affected than males
and the peak age of diagnosis is within the 5th decade of life [3,5]. The most common
cause of acromegaly and gigantism is growth hormone (GH) secreting pituitary adenoma
(PA), also called pituitary neuroendocrine tumour (PitNET) (Box 1), which represents
approximately 9–13% of all PAs.
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Box 1. Pituitary neuroendocrine tumour (PitNET).
In 2017 The International Pituitary Pathology Club suggested that the hormone-producing cells
of the pituitary are a part of the neuroendocrine system and sometimes show invasive growth,
therefore, proposed to use the phrase pituitary neuroendocrine tumour (PitNET) rather than
pituitary adenoma, to highlight the similarity with other neuroendocrine neoplasms [6]. This
suggestion has been met with some controversy [7–9]. It was suggested that there is a risk that
aligning adenohypophyseal tumours to other neuroendocrine tumours would raise unnecessary
anxiety in patients and physicians less familiar with the disease, and for the time being suggested
to carry on using the term adenoma with further discussion invited on this issue [10]. As PitNET is
a valid term, in a scientific publication its use can be deemed appropriate. We acknowledge that
both terms have advantages and disadvantages, and will use both terms in the review.
Pituitary hyperplasia is encountered less commonly, mainly as part of genetic dis-
orders such as Carney complex (CNC), McCune–Albright syndrome (MAS) or X-linked
acrogigantism (XLAG). In rare cases (less than 1%), neuroendocrine tumours producing
growth hormone releasing hormone (GHRH) or ectopic GH-secreting tumours have been
described [11–13]. Altered growth hormone regulation resulting in GH excess can ac-
company neurofibromatosis type 1, associated with optic pathway gliomas (OPG) [14].
Additionally, deficiency in the immunoglobulin superfamily member 1 (IGSF1), may result
in somatotroph neurosecretory hyperfunction in adults [15].
Most somatotroph PitNETs develop sporadically; however, in nearly 46–49% of gi-
gantism, the identifiable genetic background has been reported [16,17]. Hereditary GH-
secreting pituitary tumours can manifest as an isolated manifestation, called familial
isolated pituitary adenoma (FIPA), due to either loss-of-function mutations in aryl hy-
drocarbon receptor interacting protein (AIP) or due to gain-of-function gene duplication
in GPR101, causing XLAG. Hereditary pituitary tumours can also be part of syndromic
disease accompanied by other manifestations, often tumours of other endocrine organs,
such as in multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 4
(MEN4), MAS, CNC, or phaeochromocytoma/paraganglioma (PPGL)-pituitary adenoma
association [18–25] (Table 1).
J. Clin. Med. 2021, 10, 1377 3 of 24





Gene Location Prevalence in PituitaryTumours
Prevalence in
Acromegaly (%) Phenotype
Mean Age of Diagnosis of
GH Excess Histopathology








2nd decade of life (<30
years), male predominance,












first years of life (<5 years)
female predominance,
pituitary hyperplasia or
































































Carney Complex PRKAR1A 17q22-24
Only acromegaly/gigantism
(12% but 75% asymptomatic



















Gene Location Prevalence in PituitaryTumours
Prevalence in
Acromegaly (%) Phenotype






















type 1 NF1 17q11.2
Only acromegaly/gigantism-
around 10% in patients with






















mutation 20q13.3 Only acromegaly 40% Isolated pituitary tumour
smaller size, good response









FIPA—familial isolated pituitary adenoma; AIP—aryl hydrocarbon receptor protein-interacting protein; MEN1—multiple endocrine neoplasia type 1 gene; CDKN1B—cyclin-dependent kinase inhibitors 1b;
PRKAR1A—protein kinase A regulatory subunit type I alpha; SDHx—genes of the succinate dehydrogenase family (A, B, C or D); PPNAD—primary pigmented nodular adrenal disease; GH—growth hormone;
PPGL—phaeochromocytoma/paraganglioma.
J. Clin. Med. 2021, 10, 1377 5 of 24
2. Germline Mutations
2.1. GH Excess as an Isolated Pituitary Adenoma, FIPA
Familial isolated pituitary adenoma (FIPA) is the most common cause of familial
acromegaly. The exact prevalence of FIPA is not yet known, but it appears to be more
common than initially believed (to date, over 500 families have been described) [27–29].
FIPA is a genetically heterogenous condition, which, in its most typical form, is charac-
terised by the occurrence of two or more cases of PAs in one family in the absence of other
associated syndromic features. However, due to de novo mutations or lack of known family
history, often as a result of low disease penetrance, FIPA can also be present in apparently
sporadic—so called simplex—patients or in patients with mosaicism. FIPA families can
be divided into two subgroups: homogeneous FIPA, where all affected family members
present the same subtype of pituitary tumour, or heterogeneous FIPA, where a combina-
tion of different PA subtypes occur in the same kindreds. Most AIP mutation-positive
families have GH excess, in a homogenous form in 51% and within the heterogenous form
with prolactinomas in 24% and usually small NFPAs in 21% [28]. There is only one AIP-
positive homogenous prolactinoma family described to date [30]. Depending on genetic
background, FIPA can be divided into three subgroups: (i) AIP mutation-positive patients;
(ii) families with duplication of GPR101 (all XLAG cases have GH excess, with the vast
majority combined with prolactin excess); (iii) families with no identifiable genetic cause.
The latter represents the largest subgroup of FIPA [18,31,32]. In our cohort of 318 AIP
(and GPR101) mutation-negative FIPA families, 21% have homogenous acromegaly (repre-
senting 46% of the 147 homogeneous AIP negative families) and 32% has heterogenous
FIPA with at least member with acromegaly (59% of the 171 heterogenous FIPA kindreds).
Within the heterogenous group (171 kindreds), 29% has acromegaly and prolactinoma,
26% has acromegaly and non-functioning tumour and 4% has acromegaly and Cushing’s
disease. [28]. It is impossible to establish the exact penetrance of AIP-negative FIPA. Com-
paring AIP-positive and AIP-negative FIPA families, the number of affected subjects is
significantly lower in AIP negative kindreds, suggesting that there is lower penetrance.
2.1.1. Aryl Hydrocarbon Receptor-Interacting Protein (AIP)
Overview: AIP mutations can be identified in up to 40% of familial acromegaly and
gigantism [18,33,34]. These germline mutations occur in 10% of FIPA in our large FIPA
cohort, although previous smaller studies suggested up to 20% [28,31]. However, AIP mu-
tations are also identified in apparently sporadic (simplex) cases of PitNETs, mostly among
young-onset patients. This phenomenon is observed due to low penetrance (12.5–30%)
of the disease in AIP mutation carriers [18,31,35,36], rather than de novo mutations [18].
Current data suggest that the nature of AIP mutation (truncating or non-truncating) does
not have any effect on its penetrance [18]. In acromegaly/gigantism patients associated
with AIP mutations, a higher GH level has been observed, with no difference in insulin
growth factor 1 (IGF-1) level [28,34] and prolactin co-secretion [18].
AIP-positive GH-secreting PAs manifest earlier in comparison to AIP-negative fa-
milial [36] and sporadic cases [34]. Typically, the onset of symptoms of the AIP-positive
pituitary tumours in patients is before the age of 30 years old (65% of patients develop
symptoms <18 years) [28]. Pituitary tumours are observed, on average, 8 years earlier in
this group than in the AIP negative group [28]. At the time of diagnosis, patients often
present larger tumours with extrasellar extension, more aggressive behaviour and a higher
rate of pituitary apoplexy, especially among children [18,34,36–38]. Clinically, AIP-positive
patients with GH excess are taller than AIP-negative counterparts from FIPA families [28].
Most studies identified more males than females (60% vs. 40%) [28,34,39], but the gender
imbalance might result from ascertainment bias for genetic testing in males due to the
higher prevalence of gigantism related to a longer puberty process among boys.
Familial cascade screening can lead to early diagnosis in patients with little or no
obvious symptoms [28]. Prospectively diagnosed AIP-positive PAs are mostly less inva-
sive and present better clinical outcomes [28]. At the time of diagnosis, they are often
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microadenomas, with lower rates of suprasellar extension and cavernous sinus invasion
that correlate with the reduced rate of active diseases. These results highlight the clinical
value of genetic testing for AIP mutations among acromegalic patients and their family
members. On the other hand, with the identification of small, non-functioning lesions,
probably representing incidentalomas, screening can lead to increased anxiety and health
care spending. Follow-up of these families revealed that AIP carriers can present on a
clinical spectrum from young-onset severe cases or slowly developing cases to patients
with non-functioning stable small pituitary lesions not dissimilar to incidentalomas in the
general population. Further observational studies are required to assess the cost–benefit
ratio of the follow-up options.
To date, no somatic AIP mutation has been described [40]. However, in some studies,
sporadic somatotroph tumours show low expression of AIP [41,42].
Genetics: The AIP gene was first described in 1996 as a negative regulator of the hep-
atitis B virus X protein [43]. The association between AIP mutations and pituitary tumours
was found ten years later in 2006 in North-Finnish and Italian kindreds [35]. Subsequently,
mutation in the AIP gene was noted as the most common genetic cause of FIPA, including
familial acromegaly and gigantism cases [38]. Several sets of founder mutations have
been identified, such as the original cohort of Finnish patients (Q14* mutation) [35], but
also Italian (R304*) [44], English (a small duplication mutation) [45] and Northern Irish
(R304* independent from the Italian) cohorts, the latter providing a genetic background to
the historical and folklore Irish giant legends [46,47].
The AIP gene is a well-conserved co-chaperone protein. It has numerous partners [48],
including several heat shock proteins such as heat shock protein 90 (HSP90) and heat
shock cognate 70 (HSC70). Another binding partner of AIP protein is phosphodiesterase
subtype 4A5 (PDE4A5), an enzyme associated with the degradation of cyclic adenosine
monophosphatase (cAMP). AIP mutation results in elevated concentrations of cAMP [36,37].
Disrupting the cAMP pathway is an important factor contributing to pituitary tumouri-
genesis observed in CNC, MAS and XLAG. Dysfunction of AIP protein leads to reduced
Galphai-2 and Galphai-3 protein expression, which is responsible for inhibition of cAMP
synthesis. AIP loss is also associated with the loss of cell cycle regulator ZAC1, which plays
a role in somatostatin-related pathways [49,50]. Therefore, decreased phosphodiesterase
function, G protein dysfunction and lack of ZAC1 all could play a role in the characteristic
resistance to somatostatin analogues (SSA) [51].
While truncating mutations in AIP are obviously disease-causing, it is a challenge to
predict pathogenicity of missense variants. Various in silico as well as in vitro or in vivo
experimental approaches have been tried to support clinical genetic decisions regarding
these variants [36,37,52–54].
Diagnosis: Genetic testing includes sequencing in tumour suppressor genes. If nega-
tive, multiple ligation probe amplification (MLPA) should be performed. In AIP-positive
FIPA, genetic screening of kindreds should be performed as soon as the family agrees,
but not later than 4 years of age, based on the age of diagnosis of the youngest described
patient [55]. Up to 10 years of age, physical examination and regular body height measure-
ment should be performed [56]. Pituitary MRI is suggested to be performed first at the age
of 10 years, and then every 5 years until the age of 30. As most cases develop symptoms
before the age of 30 years, in asymptomatic AIP mutation carriers, follow-up is suggested
to be performed until this age. Then, if no pituitary pathology has been detected, the
follow-up can be relaxed or discontinued. The high frequency of pituitary incidentalomas
in the general population also should be considered in AIP-positive patients with normal
biochemical status.
Therapy: AIP-positive, GH-secreting PitNETs present more often with sparsely granu-
lated variant, aggressive behaviour and a poor response to somatostatin analogues [41,57].
Patients with AIP mutation require more often multimodal approaches including radio-
therapy and reoperation [28]. AIP-mutated somatotropinomas have been reported to have
lower somatostatin receptor type 2 (SSTR2) expression [58] and therefore lower response
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to first generations of somatostatin analogues [59]. However, in comparison to densely
granulated variants, better clinical and biochemical responses to pasireotide have been ob-
served [60]. More recently, miRNAs have been found as predictors of tumour invasiveness
and therapy outcomes. There is evidence that AIP-mutated PAs present different expres-
sions of miRNAs versus non-mutated PAs [61,62]. Upregulation of miR-34a in AIP-positive
PAs is associated with impaired treatment response to octreotide [62].
The characteristic of PAs in magnetic resonance imaging (MRI) may also predict treat-
ment response, as sparsely granulated variants correspond with T2 hyperintensity [63,64].
2.1.2. X-Linked Acrogigantism (XLAG)
Overview: XLAG is a recently described disease caused by either germline or somatic
duplications of the GRP101 gene [32]. The prevalence of XLAG varies between 7.8–10% of
gigantism patients with female predominance (2/3 of the cases) [16,65–72]. To date, less
than 40 cases of XLAG have been described. XLAG is the second most common genetic
cause of childhood onset of acromegaly after AIP-mutated somatotropinomas [16,17,68].
The phenotype of XLAG includes non-syndromic gigantism with the presentation of the
disease before the age of 5 years old. Generally, children are born with normal body
length and weight, but during the first 2 years of life, accelerated growth velocity is the
most prominent feature. Other observed manifestations are acral enlargement, coarse
facial features, headaches and sweating [17,32]. A possibly distinguishing feature between
XLAG and other pituitary gigantism cases is increased appetite, observed in one-third of
patients. Fasting hyperinsulinemia has been noted in 1/3 of cases, and 20% of patients had
acanthosis nigricans. Less frequently, sleep apnoea, extensive perspiration or abdominal
distension have been observed [16,65–72].
Pituitary pathology varies between XLAG patients from large tumours to pituitary
hyperplasia. Most patients develop mixed somatotroph/lactotroph macroadenoma with a
lower tendency to local invasion and pituitary apoplexy than patients with AIP-mutated
tumours [68]. Concomitant hyperprolactinaemia has been noted in over 85% of XLAG
patients [68]. The literature describes pituitary hyperplasia in around 25% of cases. The
potential cause of pituitary hyperplasia may result from the early onset of prenatal exposure
to increased GHRH levels. In plasma, circulating GHRH levels can be normal or slightly
elevated and in some patients, a paradoxical response in the thyrotropin-releasing hormone
test has been noted [17]. Histopathologically, pituitary tissue is characterised by sinusoidal
and lobular architecture and contains densely or sparsely granulated somatotrophs with
microcalcifications and follicle-like structures [66,68]. In most cases a low Ki-67 index has
been observed.
Genetics: GRP101 gene is located in the X26.3 region. The exact mechanism of GPR101
overexpression in pituitary tumourigenesis is not fully understood. GPR101 can lead to
activation of an orphan G protein-coupled receptor and increased cAMP levels, which is a
key factor involved in GH secretion and cell proliferation in response to GHRH [32,68]. To
date, all females have been shown to have de novo germline GPR101 duplication [32,65,68],
while mosaic mutations have been described in males except for a few familial cases
with mother-to-son inheritance [65,68,70,73]. The phenotype of patients with somatic and
germline GPR101 duplication remains the same [65,68,70,73].
Diagnosis: Genetic testing should be performed using array comparative genomic
hybridisation (aCGH) array, but in negative cases with a suggestive phenotype, alternative
methods such as copy number variation digital droplet polymerase chain reaction (PCR)
for GPR101 to detect smaller duplications [68] or high-density aCGH should be considered.
On suspicion of a mosaic XLAG mutation, analysis of affected tissue should be performed.
Preimplantation diagnosis or prenatal screening should be considered in affected mothers,
as full penetrance in familial XLAG has been observed [65,73,74].
Therapy: The treatment of XLAG patients remains challenging and often requires
a multimodal approach [65,68]. Neurosurgery is the first line treatment among patients
with pituitary tumours but often, further control of the disease requires additional medical
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therapy or radiotherapy. In cases of pituitary hyperplasia, total hypophysectomy could
be an effective surgical treatment with the obvious disadvantage of complete hypopitu-
itarism [75]. In patients not controlled by surgery, pegvisomant alone or combined with
somatostatin analogues or dopamine agonists is an effective treatment and successfully
controls linear growth [65,72,76].
2.2. Acromegaly as a Part of Systemic Disorder
2.2.1. Mutliple Endocrine Neoplasia Type 1 and Type 4 (MEN1 and MEN4)
Acromegaly in MEN1: One fourth of PitNETs related to MEN1 are GH-secreting
tumours [26,77–79]. Among all MEN1 patients, acromegaly occurs in about 10% of cases.
Conversely, MEN1 mutations have been described in 1.2% of sporadic acromegaly patients
younger than 30 years [80] The prevalence of patients with acromegaly and MEN1 phe-
notype (defined as occurrence of at least one other MEN1-associated tumour) has been
noted in 6.6% of 414 patients with acromegaly, but the prevalence of MEN1 mutations in
this group is much lower [81]. The probability of positive genetic results rises with the
occurrence of three types of endocrine tumours [81].
The prevalence of primary hyperparathyroidism among patients with acromegaly is
higher than in the general population (6.1% vs. 0.86%) [81,82]. In several studies, patients
with acromegaly presented increased calcitriol levels and fibroblast growth factor 23. How-
ever, the exact mechanism of this relationship between GH excess and hyperparathyroidism
has not been clarified yet [83].
The age at the diagnosis of acromegaly in the course of MEN1 is around 40 years [84].
GH-secreting PAs in MEN1 patients are often macroadenomas with local invasion, pluri-
hormonal profile and poor response to medical treatment but still better clinical outcomes
in comparison to AIP-mutated PAs [85]. Pituitary hyperplasia alone or coexisting with
a pituitary tumour is more common in patients with MEN1/MEN4 compared to MEN1-
negative tumours [86]. In some MEN1 patients, poorly differentiated PIT1-lineage tumours,
previously known as “silent subtype 3 adenoma”, have been observed [87], with a variable
combination of GH, prolactin, α-subunit and thyroid-stimulating hormone. In patients
with acromegaly and MEN1 syndrome, GHRH-secreting pancreas tumours should be
considered [88]. Ectopic GHRH and GH production due to lung neuroendocrine tumour re-
lated to MEN1 mutation has been found only in one patient [89]. Gigantism associated with
MEN1 mutation occurs in approximately 1% of cases [16], this could be due to a pituitary
tumour or, rarely, due to a GHRH-secreting pancreas tumour [90]. Possible coexistence of
acromegaly due to pancreatic GHRH excess and prolactin-secreting or non-functioning
pituitary tumour remains a diagnostic challenge in MEN1 patients.
Overview: PitNETs occur in 30–40% of patients with MEN1 syndrome, in addition
to hyperparathyroidism (95–100% of cases) and pancreatic neuroendocrine tumours (60%
of cases). Other common but non-endocrinological manifestations (up to 85% of cases)
include cutaneous skin lesions (angiofibromas, collagenomas, café-au-lait macules) [84,91].
PAs in general could be the first manifestation in about 20% of MEN1 cases, and many of
these are in childhood or adolescence. Some authors suggest screening MEN1 gene in this
age group [80,92]. MEN1 mutated PAs manifest predominantly in the 4th decade of life,
but various ages of onset have been noted (from 5 years to 90 years). The most common
clinically presenting pituitary tumour type is prolactinoma (60% of cases), followed by non-
functioning pituitary adenoma (NFPA) and somatotropinoma [26,77–79]. However, recent
studies have shown increased numbers of NFPA among asymptomatic MEN1 patients as
a result of family cascade screening [93]. The phenotype of prospective diagnosed PAs is
similar to sporadic cases.
Genetics: Inactivating mutation of the MEN1 gene, located on chromosome 11q13,
was first reported in 1997 [94], but the phenotype of MEN1 syndrome was first noted in a
patient with acromegaly and enlarged parathyroid glands by Erdheim in 1903. The MEN1
gene contains of 10 exons and encodes a 610 amino acids protein, menin [95]. To date, over
1800 pathogenic gene variants have been described [96,97]. More recently, MEN1 mosaic
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mutations have also been reported [98,99]. Most pathogenic germline MEN1 variants are
frameshift mutations (42%), followed by nonsense mutations (14%), missense mutations,
splice site mutations and large deletions [96,97]. Inactivating mutations of MEN1 lead
to premature menin truncation and its impaired activity. The menin function has been
proven in cell proliferation, cell signalling, transcriptional regulation and genome stability
Nevertheless, its role in tumourigenesis has not been fully understood [84,97,100]. Menin,
as a member of the histone methyltransferase complex, regulates the expression of the
cyclin-dependent, kinase-inhibiting genes (CDK), CDKN1B (encoding p27) and CDKN2C
(encoding p18) and possibly other CDK inhibitors [101,102]. The association between the
MEN1 gene and CDK1B may explain a similar phenotype of MEN1 and MEN4 syndrome.
Diagnosis: Diagnosis of MEN1 could be (i) clinically established if a patient develops
two or more MEN1 associated tumours (pituitary and parathyroid adenoma, pancreatic
neuroendocrine tumour); (ii) by the presence of one characteristic MEN1 tumour and one
first-degree relative with confirmed MEN1 mutation or (iii) due to family cascade genetic
screening in asymptomatic carriers [77]. No direct genotype–phenotype correlation of
MEN1 has been confirmed. The importance of genetic testing has been established for an
early diagnosis and the identification of asymptomatic carriers. Genetic screening tests
should be aimed to search for sequence variation or large deletions. It is suggested to start
genetic screening at the age of 5 years [91,103]. MEN1 mutation carriers should undergo
periodic clinical screening. At the time of diagnosis, baseline biochemical, pituitary and
abdominal imaging should be performed and then repeated at 1–3 year intervals. Yearly
clinical and biochemical (serum calcium, gastrointestinal hormones, prolactin and IGF-1)
assessment is advised. Abdominal and pituitary MRI in asymptomatic mutation carriers
should be performed first at the age of 10 years [84].
Therapy: First line treatment for MEN1-associated acromegaly is the same as in
current acromegaly guidelines [77]; however, patients require neurosurgery more often
and multimodal approaches, especially paediatric cases. Recent studies of MEN1 animal
models brought up important knowledge of tissue-specific tumorigenesis mechanisms
of menin and enabled testing new treatment strategies [104,105]. It has been suggested
that MEN1 gene replacement, by the use of adenoviral vectors, would decrease pituitary
tumour proliferation. Another option is the potential use of a monoclonal antibody to the
vascular endothelial growth factor (VEGF-A), which inhibits angiogenic pathways. In a
study of MEN1 mouse models with prolactinoma, the implementation of VEGF-A resulted
in lowering of the prolactin concentration in treated animals but not controls. Blockade of
angiogenesis may be considered as a nonsurgical treatment option for benign, endocrine
tumours associated with MEN1 syndrome [106].
MEN4: About 10–20% of patients presenting a MEN1-like phenotype have no iden-
tifiable MEN1 mutations. Further genetic investigations have revealed a small number
of patients harbouring loss of function mutation in the CDKN1B gene (up to 3% of cases
with negative MEN1 results) [107–109]. The syndrome of association between MEN1 phe-
notype and CDKN1B mutations has been termed MEN4. The CDKN1B gene, located on
chromosome 12q13, encodes p27 and regulates the cell cycle. To date, less than 50 cases
with CDKN1B mutations (the majority of patients presenting with hyperparathyroidism)
have been noted, one-third of those conjoined with pituitary tumours [110–113]. Due to the
rarity of the disease, penetrance and genotype–phenotype correlation cannot be assessed
yet. Somatotroph and corticotroph PAs have been found to be the most common pituitary
tumour among symptomatic MEN4 patients. In MEN4 mutation carriers found by family
screening, NFPA has been described as the most common [110–112]. In a large cohort of
190 patients with Cushing’s disease, 2.6% had CDKN1B variants [113].
In rare MEN1 and MEN4-like patients with negative genetic results, other CDKIs
pathological variants (p15 [CDKN2B, 1%], p18 [CDKN2C, 0.5%], p21 [CDKN1A, 0.5%])
should be considered [114], as well as CDC73 gene mutation [81,115,116] (responsible
for hyperparathyroidism-jaw tumour syndrome) and CaSR mutation [115,116] (causing
familial hypocalciuric hypercalcemia).
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2.2.2. McCune–Albright Syndrome (MAS)
Acromegaly in MAS: GH-secreting pituitary tumours or pituitary hyperplasia are the
most common pituitary disease associated with McCune–Albright Syndrome. Acromegaly
is present in up to one-third of cases [117]. The mean age of onset of GH excess in MAS is
observed in the 2nd decade of life, and the incidence is significantly more frequent in males
(75%). Concomitant hyperprolactinaemia occurs in 71–92% of acromegaly cases. Gigantism
related to MAS has been described in 5% of patients with GH excess with childhood-
onset [16]; however, body height in this syndrome is also dependent on precocious puberty,
which increases bone age; therefore, this peculiar disease can be the cause of both gigantism
and abnormal short stature.
Overview: MAS is classically characterised by a triad of fibrous dysplasia, precocious
puberty and café-au-lait skin lesions [118]. The prevalence of MAS is estimated between
1/100,000 and 1/1,000,000 [118]. The variety of endocrinological manifestations in addi-
tion to GH excess includes hypercortisolaemia (due to nodular adrenal hyperplasia), or
thyrotoxicosis. The suspicion of MAS should be considered when acromegaly/gigantism
is associated with other syndromic features of this disease. Probably, the oldest known case
of MAS is the Tegernsee giant, who died in 1876. He presented juvenile gigantism (body
height 230 cm) with concomitant fibrous dysplasia [119].
Genetics: MAS is caused by mosaicism for mutations in GNAS gene, located at chro-
mosome 20q13.3. The phenotype of MAS is dependent on the cell type and the number of
affected tissues. The GNAS gene encodes the stimulatory α subunit of guanine nucleotide-
binding protein [120,121]. A gain-of-function mutation in the GNAS gene, affecting codons
Arg201 and Gln227, results in a constitutively activated cAMP pathway and leads to persis-
tent GH hypersecretion and cell proliferation. [122–124]. The consequences in the pituitary
include overproduction of GH and sometimes also prolactin and hyperplasia or tumour.
Diagnosis: The diagnosis can be made clinically by a complete physical and biochem-
ical evaluation of patients. When the clinical, radiological and histopathological analysis is
unclear, genetic testing should be performed. Molecular diagnosis could include Sanger
sequencing of samples of affected tissue, and while this technique had a lower sensitivity
from peripheral blood lymphocytes, more recently, digital droplet PCR from whole blood
or from circulating cell free DNA showed 80% sensitivity [125].
Therapy: First-line treatment of acromegaly/gigantism related to MAS with pituitary
hyperplasia is somatostatin analogues. In resistant cases, pegvisomant alone or in combi-
nation with octreotide or lanreotide is recommended. Pasireotide has also been used in
the treatment of GH excess in MAS [126]. If concomitant hyperprolactinaemia occurs, a
dopamine agonist should be added as well. In patients not responding to pharmacologi-
cal therapy, pituitary surgery should be considered. Neurosurgery is challenging due to
concomitant skull base fibrous dysplasia, as high vascularity of these bony lesions gives
a high risk of haemorrhage. If operated, total hypophysectomy is suggested, as in most
of the cases, the whole gland is involved. Radiotherapy of the pituitary gland should be
carefully considered for severe disease if previously therapy options have failed. Radiation
of associated bone lesions may lead to malignant transformation of sarcoma [117].
2.2.3. Carney Complex (CNC)
Acromegaly in CNC: In up to 75% of patients with CNC, the asymptomatic elevation
of GH, IGF-1 and/or prolactin or abnormal response to the thyrotropin-releasing hormone
is observed. Clinically evident acromegaly due to pituitary tumour occurs in 10–12% of
cases, with slight female predominance [127,128]. Acromegaly was the first manifestation
of CNC in four patients reported in the literature; however, at the time of diagnosis, a
majority of patients had several other CNC symptoms [128]. Pituitary manifestation in-
cludes pituitary tumour, pituitary hyperplasia or a combination of both [129]. Acromegaly
manifests in the 3rd decade of life [130], but gigantism related to CNC has also been
noted. GH-secreting PitNETs are often multifocal, surrounded by somatomammotrophic
hyperplastic tissue.
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Overview: CNC is a rare genetic disorder with multiple endocrine and non-endocrine
symptoms, with an autosomal dominant inheritance and high penetrance for some man-
ifestations (>95% by the age of 50). It was originally described by Professor Carney as a
“complex of myxomas, spotty pigmentation, and endocrine overactivity” in 1985 [131].
However, the first (now molecularly confirmed) CNC patient was reported by Professor
Harvey Cushing in 1913. The patient presented acromegaly due to pituitary tumour,
skin pigmentation and adrenal pathology [132]. The analysis of archive tissue revealed
a PRKAR1A mutation. The most common endocrinological manifestation is adrenocorti-
cotropic hormone (ACTH)-independent Cushing’s syndrome due to primary pigmented
nodular adrenal disease (PPNAD). The prevalence of Carney complex is unknown. To
date, over 700 cases have been described [133].
Genetics: The majority of CNC cases are familial. Most are caused by a germline-
inactivating mutation mainly in the PRKAR1A gene (CNC1), located on the 17q22-24
locus [134,135], but recently other protein kinase A regulatory subunit 1α (PKA) mutations,
including PRKACB, have also been described [136–138]. In approximately 30% of cases,
CNC occurs as a consequence of a de novo mutation. The study with the largest number of
patients with Carney complex has found a genotype–phenotype correlation [127]. Patients
with large deletions of PRKAR1A develop the diseases earlier with a more severe phenotype,
including metastatic psammomatous melanotic schwannoma [139].
PRKAR1A is composed of two catalytic and 2 regulatory subunits and is implicated
in transcriptional regulation, cell proliferation and apoptosis. Inactivating mutations of
PRKAR1A lead to uncontrolled activation of cAMP-dependent kinase activity in affected
tissues [135]. Carney complex 2 locus (CNC2), located on chromosome 2p16, accounts for
20% of cases; however, the responsible gene at this locus has not been found yet [140,141].
The incidence of acromegaly was similar in CNC1 and CNC2 groups.
Diagnosis: Diagnosis of Carney complex in a patient may be established clinically
if two or more major criteria are present (characteristic skin lesions, cutaneous and heart
myxomas, PPNAD, acromegaly, large-cell calcifying Sertoli cell tumour or characteristic
calcification of testis, thyroid carcinoma or multiple hypoechoic nodules, breast ductal ade-
noma psammomatous melanotic schwannomas, blue nevus, osteochondromyxoma) [19].
Another way to confirm CNC diagnosis is the occurrence of one major criterion and an
affected first-degree relative or a known inactivating PRKAR1A mutation. Genetic testing
may be offered for patients with two major diagnostic criteria or for relatives of patients
with Carney complex. Molecular techniques include Sanger sequencing. In negative cases,
copy number variant analysis by CGH or deletion testing should be performed.
Therapy: To date, there is no specific treatment approach for acromegaly in CNC cases,
and guideline on the management is the same as in sporadic cases. In a great majority
of patients, surgery alone or combined with SSA has been used. If multiple pituitary
tumours are present, partial or complete hypophysectomy should be performed. Some
authors suggest that due to overactivation of cAMP signalling in CNC patients, the use
of SSA theoretically would be beneficial. However, resistance to SSA treatment has been
observed [128].
2.2.4. Phaeochromocytoma/Paraganglioma (PPGL) and Pituitary Adenoma Association
(3Pa)—SDHx/MAX Mutations
Overview: The coexistence of pituitary adenoma with PPGL was first described in
1952 in a patient with acromegaly and phaeochromocytoma [142]. Genetic predisposition
of this rare condition has been relatively recently found in 2009 in a familial case of
prolactinoma with paraganglioma and SDHB mutation [143]. Subsequently, in 2012, a
patient with aggressive GH-secreting PitNETs with bilateral phaeochromocytomas and a
pathogenic variant of SDHD mutation was described [144]. To date, <100 cases of PPGL
and pituitary adenoma association, also known as “three P association” (3Pa), have been
described worldwide, which represent a genetically heterogenous group [22,145,146].
Acromegaly with SDHx mutation: The most common genetic cause of 3Pa is a
germline loss of function mutation of the succinate dehydrogenase (SDH)x gene. GH-
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secreting PAs associated with SDHx mutations tend to be aggressive macroadenomas.
To date, 4 GH-PitNETs with an SDHx mutation have been described (SDHD and SDHB
mutations). Gigantism related to SDHx mutation has not been reported yet. Three pa-
tients harboured macroadenomas (data about tumour size was not available in the 4th
case), and they were treated with SSA alone or combined with surgery. The age at the
diagnosis of acromegaly varies from 37 to 84 years old [147]. A unique histopathological
feature of pituitary adenoma with SDHx mutations is intracytoplasmic vacuoles, which
can correspond to the presence of autophagic bodies [148]. More recently, SDHx mutations
have been observed in patients with an isolated pituitary tumour and without personal or
familial history of PPGL, but none of them had somatotropinoma (3 prolactinomas out of
263 patients with PAs) [146].
Genetics: There are several genes encoding the SDH protein complex (SDHA, -B, -C,
-D or SDHA2F). This multimeric enzyme plays a crucial role in tricarboxylic acid or the
Krebs cycle and respiratory chain. Germline mutation of SDH results in the accumulation
of oncometabolites that inhibit degradation of hypoxia transcription factor (HIFα) [149].
The penetrance of pituitary tumours in SDHx mutation-positive patients is very low
(1% of cases).
Acromegaly with MAX mutation: The association of PPGL and PA has been de-
scribed in a few cases due to MYC-associated factor X mutations (MAX). They were soma-
totroph macroadenomas, including a childhood-onset case, and prolactinomas [150,151].
Patients required multimodal approach, as surgery alone was not sufficient. The combi-
nation of SSA with cabergoline and pegvisomant, as well as radiotherapy, was used [150].
Patients with germline MAX mutation may also develop other systemic manifestations
like renal oncocytoma or lung cancer [152].
Genetics: The MAX gene is located on chromosome 14q23.3. MAX interacts with
other parts of the MAX-MLX network, which is responsible for the integration of cellular
signals and modulates the expression of another gene [153]. Germline MAX mutations are
associated with tumourigenesis involving neuroendocrine cells, renal tumours or small cell
lung cancer [152,154]. Point mutations and small exonic and intronic deletions [150,151] of
MAX have been linked to PAs.
The association of pituitary tumours and PPGL may also appear due to MEN1 muta-
tion (to date, one mixed GH/PRL macroadenoma out of four PitNETs [148]). NF1 can be
associated with PPGL and GH excess (see above). Other germline mutations, including
RET and TMEM127, have also been described with pituitary adenomas, but more data are
needed to asses if they are indeed involved in pituitary tumourigenesis or if these cases are
coincidences. [148,155,156]. A rare clinical situation of acromegaly due to ectopic GHRH
production by PPGL (usually phaeochromocytoma) has also been described [157,158],
including a MAX mutation positive case [159].
2.3. Other Syndromic Disease Associated with Germline Mutations and GH Excess without Visible
Pituitary Tumour/Pituitary Hyperplasia
2.3.1. Neurofibromatosis Type 1 (NF1)
Acromegaly in NF1: Clinical features of acromegaly and gigantism with GH excess
have been observed in 10% of children with NF1 and symptomatic OPG without visible
pituitary tumour. In these patients, the OPG involved the chiasm and reached the optic
radiations and temporal regions. The specific mechanism of NF1 mutations leading to GH
excess has not been identified yet [14,160]. The causes of GH excess may result from the
loss of hypothalamic somatostatinergic inhibition, increase in GHRH stimulation, and the
role of activation of hypothalamic GPR101 is also possible. Interestingly, the GH excess
often improves later in life. Somatostatin analogues and pegvisomant have been reported
as an effective treatment in patients with NF1 and GH excess [14,161,162]. Normalisation of
GH after SSA treatment has been observed [160,163]. NF1 and bona fide pituitary adenoma
is extremely rare and possibly a coincidence, only reported in two patients [163,164],
including a 68-year-old female with somatotropinoma, hyperparathyroidism and follicular
thyroid carcinoma. Genetic testing confirmed NF1 mutation and excluded MEN1 mutation.
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The PA tissue showed no loss of the wild type allele of the NF1 gene, but harboured a
somatic GNAS p.R201C mutation, not supporting NF1 being causative in pituitary adenoma
development. In the other published case with NF1 mutation and somatotroph PA, somatic
changes were not assessed [164].
Overview: NF1 is one of the most common genetic disorders, with the prevalence es-
timated at around 1:2500–1:3500 live births. This autosomal-dominant syndrome is caused
by an inactivating mutation of the NF1 gene, located on chromosome 17q11.2. It encodes
neurofibromin, a protein involved in cell growth and proliferation, by inhibiting RAS
activity and regulation of cAMP levels [165]. The most common characteristic features are
cutaneous neurofibromas, cafe-au-lait skin lesions, intertriginous freckling, Lisch nodules
and brain tumours, including the most common optic pathway glioma [166]. The diagnosis
can be made clinically if the patient presents two or more signs of the condition.
2.3.2. Deficiency of the Immunoglobulin Superfamily Member 1 (IGSF1)
Recent data revealed that IGSF1 deficiency results in somatotroph neurosecretory
hyperfunction [15]. The IGSF1 gene, located on the X chromosome, is highly expressed
in the hypothalamus and pituitary. Its loss-of-function mutations cause central hypothy-
roidism, hypoprolactinaemia and macroorchidism. Additionally, 52.4% of adult patients
with germline IGSF1 mutation present acromegalic facial features as well as organ changes
due to GH excess. Tall stature does not occur. The average age of onset of GH hypersecre-
tion has not been defined yet. Biochemically, the IGF-1 level rises usually above the mean
(above 1 SDS). A germline IGSF1 variant has been identified in three family members with
XLAG-related gigantism, but the reported variant has up to 0.01 minor allele frequency
and has been reported as benign by ClinVar, and is therefore unlikely to be related to
the phenotype [167]. More research is required to define the exact role of IGSF1 in the
regulation of the somatotroph axis.
2.3.3. Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex is an autosomal-dominant genetic disorder caused by
loss-of-function mutation in either the TSC1 gene on chromosome 9q34.13 or the TSC2
gene on chromosome 16p13.3. The phenotype of the disease includes multiple hamartomas
of the brain, lungs, heart, skin and kidney. To date, four patients with the TSC mutation
and pituitary tumour have been described, including only one somatotropinoma [168–171].
More data are needed to determine the exact role of TSC in pituitary tumourigenesis.
3. Somatic Variants in GH-Secreting PitNETs
3.1. GNAS
The first identified and the most common somatic mutation found in isolated GH-
producing PitNETs is in the GNAS gene at the 201 and 227 codons [172,173], with a
frequency of 30–40% of sporadic acromegaly (range 10–50% depending on the ethnicity
of patients) [174]. GNAS-mutated somatotroph tumours are smaller and less likely to be
invasive but contribute to higher GH and IGF-1 levels. In comparison to AIP and GPR101
mutated PAs, GNAS-positive tumours arise in older patients and show a better response to
first-generation somatostatin analogues treatment [175]. Furthermore, in GNAS-mutated
PAs, higher expression of dopamine receptor 2 has been observed. GNAS status could
have a potential value in predicting better treatment response to dopamine agonists [172].
However, in a study of genome-wide sequencing, GNAS mutation has been found in
5 out of 8 plurihormonal PAs secreting GH and prolactin and in 9 out of 23 pure GH
somatotropinomas. Alterations of DNA methylation have also been linked with GNAS
mutation [172]. In a recent study, PIT1 lineage tumours showed global hypomethylation,
chromosome alterations and transposable element overexpression [172]. A negative cor-
relation between DNA hypomethylation and chromosome instability has been observed.
However, in GNAS mutated tumours, DNA hypomethylation and limited chromosomal
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alterations have been noted. In GNAS wild-type GH-PitNETs, unexpectedly, gonadotroph
marker (SF1) expression has been described [172].
To date, no association has been observed between GNAS mutation and granulation
patterns in histopathology results [176,177]. GNAS is an imprinted gene with maternal allele
expression in normal pituitary tissue. In GNAS positive patients, mutations are almost al-
ways located on the maternal allele due to paternal imprinting [178,179]. Somatic mosaicism
of the GNAS gene results in the previously described McCune–Albright syndrome.
3.2. Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR)
In around 30% of GH-secreting PAs with negative GNAS mutation, GIPR is expressed
at a significantly higher level than in the normal pituitary gland. Clinically, in these patients,
paradoxical increase in GH after oral glucose load test has been observed [180]. In a study
analysing 496 patients with acromegaly, a paradoxical response was associated with older
age at the diagnosis, smaller and less invasive PAs and better treatment outcomes [181].
The potential mechanism could be explained by increased gastric inhibitory peptide (GIP)
stimulation and therefore higher GH levels in the glucose load test. The GIP/GIPR axis
stimulates GH secretion by mimicking the cellular pathways triggered by GHRH stim-
ulation [180,182,183]. A paradoxical rise of GH to oral glucose in acromegaly may help
to predict clinical characteristics of PitNET that may influence therapy approaches [184].
However, other biological factors, like BMI, oral oestrogen intake, diabetes mellitus or
hyperthyroidism should be taken into account when interpreting GH values after glucose
suppression [185].
3.3. Other Genes
Studies using whole-genome sequencing and whole-exome sequencing did not find
any consistently recurrent somatic mutations. However, several somatic variants associated
with the cAMP pathway, calcium signalling and ATP signalling have been observed
(Table 2), which may suggest the important role of these pathways in the pathogenesis of
GH-secreting PAs [186,187].
Table 2. Somatic variants associated with somatotroph PitNETs and with the cyclic adenosine
monophosphatase (cAMP) pathway, calcium signalling, and adenosine triphosphate (ATP) signalling
[186,187].





























In patients with DICER1 mutations and pituitary blastoma, immunohistochemistry
for GH was positive in 10 out of 14 studied tumours. Biochemically, serum GH and IGF-1
levels were not elevated. Clinically, patients did not present increased growth velocity or
tall stature [188].
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In a significant proportion of cases, the genetic background of pituitary tumourigenesis
is still not fully understood. Further studies found a relationship between epigenetic modifi-
cations and pituitary tumourigenesis. Epigenetic alterations may occur at chromatin levels
such as DNA methylation and histone modification, or via non-coding RNAs, microRNAs
or proteomics [189]. Also, the tumour microenvironment, including a variety of non-
neoplastic and non-cellular elements, may modulate pituitary tumourigenesis [190,191].
4. Recommendations for Genetic Screening in Acromegaly and Gigantism
Main determinants of genetic testing in patients with acromegaly and gigantism are
the age of onset of symptoms, pituitary tumour type (pituitary alone or with concomi-
tant hyperplasia, histopathology subtype), family history or manifestations of syndromic
diseases in patients or their family members (Figure 1) [192].
Figure 1. Suggested algorithm of genetic screening of GH excess. GH, growth hormone; GHRH,
growth hormone releasing hormone; XLAG, X-linked acrogigantism; AIP, aryl hydrocarbon receptor-
interacting protein; MEN1, multiple endocrine neoplasia type 1.
While today the majority of genetic testing in genetically heterogeneously determined
diseases is based on gene panel testing, we can draw characteristic clinical aspects pointing
to specific characteristic genes. In infant-onset GH excess (usually already manifesting
before the age of 1 year, but all cases by age of 5), X-linked acrogigantism should be
considered. If blood-derived GPR101 duplication testing is negative using a CGH array,
analysis of affected tissue or alternative tissue DNA and gene-specific methods (ddPCR)
should follow before ruling out this diagnosis. In cases of childhood-onset of GH, excess
AIP mutations represent the highest likelihood. While most cases are macroadenomas at
clinical presentation, a few microadenomas have also been described. MEN1 syndrome-
related childhood-onset GH-secreting adenoma or GHRH-secreting tumours are rare but
described. MEN1 and CDKN1B testing is recommended in patients with personal or family
history of kidney stones, neuroendocrine tumours or pituitary tumours. McCune–Albright
and Carney complex are usually clinical diagnoses, but genetic testing can confirm the
clinical findings. Association with paragangliomas or phaeochromocytomas should prompt
panel testing for associated genes for these diseases.
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Genetic testing can provide both advantages and disadvantages. We should consider
the disadvantages: (i) psychological burden of increasing anxiety, guilt and depression due
to carrying a genetic alteration and transmitting it to offspring, (ii) identifying variants with
uncertain significance leading to uncertainty and (iii) costs. Advantages, however, usually
outweigh the disadvantages: (i) to family members for early diagnosis via cascade screen-
ing [18,34,39,77], enabling better prognosis, (ii) to patients to search for other syndromic
manifestations, (iii) to provide an explanation for the disease, which patients often greatly
appreciate, even if no further clinical or therapeutic advantages follow and (iv) helping to
understand disease mechanisms that may lead to novel future therapies. Careful discussion
and individualised decision-making help to achieve balanced clinical management.
To date, there is no universally accepted genetic panel test available for acromegaly
patients, but most reference laboratories offer next-generation sequencing panel testing
including several genes like AIP, MEN1, CDKN1B, PRKAR1A, SDHA, SDHB, SDHC and
SDHD rather than sequencing of particular genes. If multiple endocrine neoplasia is sus-
pected, a gene panel including AIP, CDC73, CDKN1B, MEN1, RET genes is recommended
(https://www.exeterlaboratory.com/, 19 March 2021).
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